AbbVie gets FDA approval for antibiotic treatment Emblaveo (update)
AbbVie (NYSE:ABBV) said it has received FDA approval for the intravenous antibiotic treatment Emblaveo, which was co-developed with Pfizer (NYSE:PFE). The FDA approved Emblaveo, a combination of ...
RGA raises intermediate-term ROE target to 13%-15% with expanded growth focus
Q4 2024 Management View The CEO, Tony Cheng, highlighted record performance with adjusted operating earnings of $4.99 per share in Q4 2024. The company achieved a 15.4% adjusted operating return on ...
Biomednewsbreaks - Annovis Bio Inc. (NYSE: ANVS) CEO To Present At Oppenheimer Healthcare Conference
Annovis Bio (NYSE: ANVS) a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced that CEO Maria M ...